Deal focused on HCV
Oct 15th 2012 - Edison Investment Research today published a report on Bhp Billiton entitled "Deal Focused On HCV". In summary, the report says: Benitec's acquisition of its US-based technology licensee, Tacere Therapeutics, allows the Australian RNAi specialist to bring in-house a Phase I-ready drug candidate for Hepatitis C virus infection.
Start the conversation, or Read more at Stockopedia.
Copyright © 2018 Topix LLC